ETF showdown: ARKG vs GNOM, which genomics fund wins?

The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener. Both promise pure-play exposure to gene editing, sequencing, and precision medicine, but they differ structurally. One is Cathie Wood's discretionary bet on unprofitable innovators. The other tracks the Solactive Genomics Index and quietly holds Moderna and Vertex next to the moonshots. Over the past year, that structural gap produced a 32.0% year-to-date move in one and a 17.0% move in the other, going in the same direction but at very different speeds.

What Each Fund Is Actually Betting On

ARKG is a concentrated wager on pre-revenue and early-revenue platforms. Its top three positions, Twist Bioscience at 9.2%, Tempus AI at 7.6%, and Absci at 7.0%, together make up roughly 23.8% of the portfolio. Gene-editing names account for about 18%, and AI-driven drug discovery adds another 16%. The fund needs cheap capital, risk appetite, and clinical wins to work. Rates falling and biotech M&A reviving are the environment it is built for.

GNOM makes a broader bet. It holds 51 positions, anchored by cash-flowing names: Illumina at 4.6%, Moderna at 4.3%, and Vertex Pharmaceuticals at 3.8%, alongside Bristol-Myers Squibb, Gilead, and AstraZeneca. Passive rebalancing and index reconstitution dilute single-name blowups. The implicit bet is that genomics as a category compounds even if the flashiest names disappoint.

Where the Difference Shows Up

Over the five-year window, ARKG is down 55.4% from July 2021 through July 2026, while GNOM is down 42.6% over the same stretch. That is the small-cap, unprofitable-biotech tax showing up in real numbers after the 2021 to 2022 rate shock. Over 10 years, ARKG is up 110.3%, capturing the 2020 pandemic surge, while GNOM is down 12.5% since April 2019. In the past 12 months, GNOM's 55.1% gain edged ARKG's 53.6%, evidence that large-cap biotech participated in the rally without the whipsaw.

The Practical Comparison

The asset gap matters. ARKG's roughly $1.4 billion in net assets gives it far tighter spreads than GNOM's $75 million. Retirement investors placing larger orders will feel that liquidity difference.

The Verdict

For a retirement-focused investor, GNOM screens as the more defensible core exposure. Its blend of large-cap pharma anchors and small-cap innovators dampens the drawdowns that made ARKG a wealth-destroying position between 2021 and 2023. ARKG fits an investor who already owns broad healthcare exposure and wants a satellite position sized to survive another 50% drawdown while capturing the upside if gene-editing platforms reach commercialization.

What would flip that call? Sustained falling rates plus a wave of biotech acquisitions targeting unprofitable platform companies. In that environment, ARKG's concentration in the likes of Tempus AI, Twist Bioscience, and CRISPR Therapeutics becomes the feature, not the bug.

Contact [email protected] for any questions or corrections.